Heart disease remains the leading cause of death in the United States, with cardiovascular disease accounting for more than 940,000 deaths in 2022, according to the American Heart Association. The problem is worsening, and annual health care costs for cardiovascular conditions are projected to rise from $393 billion in 2020 to $1.4 trillion by 2050. Into this costly healthcare burden steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company applying artificial intelligence, epigenetics, and genetics to detect coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw.
What makes Cardio Diagnostics’ approach distinct is its ability to detect coronary heart disease earlier and with high sensitivity. The company's recent commercial and regulatory milestones provide additional shape to the investment thesis. The scale of the problem is difficult to overstate, with one person dying every 34 seconds from cardiovascular disease, according to the AHA.
Cardio Diagnostics’ technology leverages epigenetic markers—chemical modifications to DNA that can indicate disease risk—combined with AI algorithms to analyze blood samples. This approach aims to identify heart disease at earlier stages than traditional diagnostic tools, potentially reducing mortality and healthcare costs. The company's focus on coronary heart disease, which includes forms that often go undetected by standard methods, positions it as a unique player in the precision medicine space.
For more information on the company's latest news and updates, visit the company’s newsroom at https://ibn.fm/CDIO. Full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
